

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

NCT05896020

Status	RECRUITING
Phase	Phase 2
Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Enrollment	225 participants

Key Eligibility Criteria

Inclusion (5)

- The subjects voluntarily joined the study and signed the ICF.
- Measurable disease, as defined by RECIST v1.1.
- The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
- Life expectancy e 12 weeks.
- Subjects with advanced cervical cancer, recurrent ovarian cancer and endometrial cancer.

Exclusion (7)

- Symptomatic, untreated or active central nervous system metastases.
- Previously received antitumor-conjugated drugs with the following characteristics: topoisomerase I inhibition in the composition Preparations, such as Enhertu (DS-8201a), U3-1402, etc..
- Have uncontrolled or severe cardiovascular disease.
- With any active autoimmune disease or history of autoimmune disease.
- Patients with active hepatitis B or hepatitis C.

... and 2 more (see full listing online)

Locations (1 total)

Qilu Hospital of Shandong University, Jinan, Shandong, China